cannabis indica

Doenças Neurodegenerativas

termo de indexação original: Neurodegenerative Issues

O acervo do Cannabis Indica reúne 299 estudos científicos que tocam a condição Doenças Neurodegenerativas, publicados entre 1981 e 2024. Pela leitura automatizada, 250 (84%) foram classificados como favoráveis, 35 (12%) como inconclusivos e 14 (5%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (143 estudos), seguido de estudo em animais (81). Os compostos mais presentes são Endocanabinoide (não especificado), Anandamida (AEA) e 2-Araquidonoilglicerol (2-AG). Aparece com frequência ao lado de Inflamação, Doença de Alzheimer e Estresse Oxidativo.

Estudos indexados
299
Período coberto
1981–2024
Favoráveis
250 · 84%
Inconclusivos
35 · 12%
Desfavoráveis
14 · 5%
Termo original
Neurodegenerative Issues

O acervo em números

Tipo de estudo

Metanálise143
Estudo em Animais81
Estudo Laboratorial38
Ensaio Clínico Duplo-Cego15
Ensaio Clínico11
Metanálise Clínica11

Direção do resultado

Favorável250
Inconclusivo35
Desfavorável14

Por década

1980s1
1990s4
2000s22
2010s114
2020s158

299 estudos

Filtrar e buscar no acervo →
  1. 2024

    A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood

    DesfavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisDisfunção Cognitiva
  2. 2024

    Alzheimer's disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging

  3. 2024

    Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present)

  4. 2024

    Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial

  5. 2024

    Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial

    DesfavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisDisfunção CognitivaInsônia e Distúrbios do Sono+1
  6. 2024

    The Impact of Cannabis Use on Cognition in People with HIV: Evidence of Function-Dependent Effects and Mechanisms from Clinical and Preclinical Studies

    InconclusivoMetanáliseInflamaçãoDisfunção CognitivaHIV/AIDS
  7. 2024

    The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders

    FavorávelMetanáliseDorInflamaçãoEpilepsiaEndocanabinoide (não especificado)+2
  8. 2023

    A Case of Panic Attacks Developing After 10 Years of Chronic Cannabis Use in a Patient With No Prior Psychiatric History

    DesfavorávelMetanáliseDorCâncerInflamaçãoTetraidrocanabinol (THC)Canabigerol (CBG)+13
  9. 2023

    Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance

  10. 2023

    Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms

    DesfavorávelEnsaio Clínico Duplo-CegoDisfunção CognitivaDoença de Parkinson
  11. 2023

    Exploring the Neuroprotective Effects of Spirulina platensis: Insights Into Hemorrhagic Volume and Histological Outcomes

  12. 2023

    Hippocampal differential expression underlying the neuroprotective effect of delta-9-tetrahydrocannabinol microdose on old mice

    FavorávelEstudo em AnimaisInflamaçãoDisfunção Cognitiva
  13. 2023

    Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial

  14. 2023

    Multi-Targeting Intranasal Nanoformulation as a Therapeutic for Alzheimer's Disease

    FavorávelEstudo em AnimaisDisfunção CognitivaDoença de AlzheimerDemência
  15. 2023

    Phytocannabinoids: Pharmacological effects, biomedical applications, and worldwide prospection

    InconclusivoMetanálise ClínicaDorCâncerAnsiedadeTHC FarmacêuticoTHC:CBD Farmacêutico+9
  16. 2023

    Preventing Neurocognitive Decline in Adults Aging with HIV: Implications for Practice and Research

    FavorávelMetanáliseInflamaçãoDisfunção CognitivaDoença de Alzheimer+3
  17. 2023

    Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence

  18. 2023

    Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer's disease: A systematic review and meta-analysis of animal studies

  19. 2023

    Screening of Spirulina Components for Anti-Parkinson's and Anti-Alzheimer's Activity by in Silico Methods and Docking Studies

    FavorávelEstudo LaboratorialCâncerEstresse OxidativoDoença de AlzheimerFicocianina+2
  20. 2023

    Structural organisation of perisomatic inhibition in the mouse medial prefrontal cortex

    InconclusivoEstudo em AnimaisDisfunção CognitivaEndocanabinoide (não especificado)
  21. 2023

    Synergetic effect of β-asarone and cannabidiol against Aβ aggregation in vitro and in vivo

  22. 2023

    The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

    FavorávelMetanálise ClínicaDorDependência QuímicaAnsiedade+2
  23. 2023

    Therapeutic effect of cannabidiol on myocardial arachidonic acid content in various lipid fractions in a rat model of obesity

  24. 2023

    Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial

    FavorávelEnsaio Clínico Duplo-CegoCOVID-19Palmitoiletanolamida (PEA)
  25. 2022

    A narrative review of molecular mechanism and therapeutic effect of Cannabidiol (CBD)

    FavorávelMetanáliseDorCâncerInflamação+5
  26. 2022

    A review on structurally diversified synthesized molecules as monoacylglycerol lipase inhibitors and their therapeutic uses

  27. 2022

    A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment

    FavorávelMetanáliseDorCâncerAnsiedadeAnandamida (AEA)Tetraidrocanabinol (THC)+25
  28. 2022

    Biochemical aspects and therapeutic mechanisms of cannabidiol in epilepsy

  29. 2022

    Cannabidiol (CBD) treatment improves spatial memory in 14-month-old female TAU58/2 transgenic mice

    FavorávelEstudo em AnimaisAnsiedadeDisfunção CognitivaDoença de Alzheimer
  30. 2022

    Cannabidiol Enhances Microglial Beta-Amyloid Peptide Phagocytosis and Clearance via Vanilloid Family Type 2 Channel Activation

    FavorávelEstudo LaboratorialDoença de AlzheimerEndocanabinoide (não especificado)
  31. 2022

    Cannabidiol for the treatment of autism spectrum disorder: hope or hype?

  32. 2022

    Cannabidiol induces autophagy and improves neuronal health associated with SIRT1 mediated longevity

    FavorávelEstudo LaboratorialCondições GeriátricasSarcopenia
  33. 2022

    Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer’s Disease Rat Model: A Proof-of-Concept Study

    FavorávelEstudo em AnimaisInflamaçãoDoença de AlzheimerSíndrome Metabólica+1
  34. 2022

    Cannabidiol, a Regulator of Intracellular Calcium and Calpain

    FavorávelMetanálise
  35. 2022

    Cannabinoid CB 2 Receptors Modulate Microglia Function and Amyloid Dynamics in a Mouse Model of Alzheimer's Disease

    FavorávelEstudo em AnimaisInflamaçãoDoença de AlzheimerEndocanabinoide (não especificado)
  36. 2022

    Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report

    FavorávelMetanáliseInflamaçãoAnsiedadeDepressão+4
  37. 2022

    Cannabinoids Reduce Extracellular Vesicle Release from HIV-1 Infected Myeloid Cells and Inhibit Viral Transcription

    FavorávelEstudo LaboratorialInflamaçãoHIV/AIDSDoenças Priônicas
  38. 2022

    Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis

  39. 2022

    Cannabinoids: Therapeutic Use in Clinical Practice

    FavorávelMetanálise ClínicaCâncerEpilepsiaDoença de AlzheimerAnandamida (AEA)Tetraidrocanabinol (THC)+16
  40. 2022

    Cannabinol inhibits oxytosis/ferroptosis by directly targeting mitochondria independently of cannabinoid receptors

    FavorávelEstudo LaboratorialEstresse OxidativoCanabinol (CBN)
  41. 2022

    Cannabis terpenes display variable protective and anti-aggregatory actions against neurotoxic β amyloid in vitro: highlighting the protective bioactivity of α-bisabolol in motorneuronal-like NSC-34 cells

    FavorávelEstudo LaboratorialDoença de Alzheimer
  42. 2022

    Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study

  43. 2022

    Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents

    FavorávelMetanáliseInflamaçãoEstresse OxidativoDoença de AlzheimerCúrcuma+4
  44. 2022

    Effect of the MAGL/FAAH Dual Inhibitor JZL-195 on Streptozotocin-Induced Alzheimer's Disease-like Sporadic Dementia in Mice with an Emphasis on Aβ, HSP-70, Neuroinflammation, and Oxidative Stress

  45. 2022

    Effects of Cannabidiol on Parkinson's Disease in a Transgenic Mouse Model by Gut-Brain Metabolic Analysis

    FavorávelEstudo em AnimaisDoença de Parkinson
  46. 2022

    Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty

  47. 2022

    Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+5
  48. 2022

    Footshock-Induced Abstinence from Compulsive Methamphetamine Self-administration in Rat Model Is Accompanied by Increased Hippocampal Expression of Cannabinoid Receptors (CB1 and CB2)

  49. 2022

    Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice

  50. 2022

    Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

  51. 2022

    Impact of the cannabinoid system in Alzheimer's diseases

  52. 2022

    Improved cognition impairment by activating cannabinoid receptor type 2: Modulating CREB/BDNF expression and impeding TLR-4/NFκBp65/M1 microglia signaling pathway in D-galactose-injected ovariectomized rats

  53. 2022

    Influence of N-Arachidonoyl Dopamine and N-Docosahexaenoyl Dopamine on the Expression of Neurotrophic Factors in Neuronal Differentiated Cultures of Human Induced Pluripotent Stem Cells under Conditions of Oxidative Stress

  54. 2022

    Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice

  55. 2022

    Medicinal Herbs in the Relief of Neurological, Cardiovascular, and Respiratory Symptoms after COVID-19 Infection A Literature Review

  56. 2022

    Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of APP Swe /PS1ΔE9 Transgenic Female Mice

    FavorávelEstudo em AnimaisInflamaçãoAnsiedadeDisfunção Cognitiva+4
  57. 2022

    Modulation of Recombinant Human T-Type Calcium Channels by Δ 9-Tetrahydrocannabinolic Acid In Vitro

    FavorávelEstudo LaboratorialDorEpilepsiaÁcido Tetraidrocanabinólico (THC-a)
  58. 2022

    Multiple regulation and targeting effects of borneol in the neurovascular unit in neurodegenerative diseases

    FavorávelMetanáliseInflamação
  59. 2022

    Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders

  60. 2022

    Neuroprotective effect of alpha-pinene is mediated by suppression of the TNF-α/NF-κB pathway in Alzheimer's disease rat model

    FavorávelEstudo em AnimaisInflamaçãoAnsiedadeDisfunção CognitivaMedicina Mente-Corpo+4
  61. 2022

    Non-psychotropic Cannabis sativa L. phytocomplex modulates microglial inflammatory response through CB2 receptors-, endocannabinoids-, and NF-κB-mediated signaling

  62. 2022

    Orchestration of the circadian clock and its association with Alzheimer's disease: Role of endocannabinoid signaling

  63. 2022

    Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice

    FavorávelEstudo em AnimaisInflamaçãoAnsiedadeObesidadePalmitoiletanolamida (PEA)+2
  64. 2022

    Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ9-tetrahydrocannabinol: a pilot study

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDepressãoTetraidrocanabinol (THC)Monoacilglicerol Lipase (MAGL)+2
  65. 2022

    Pharmacological Activation of GPR55 Improved Cognitive Impairment Induced by Lipopolysaccharide in Mice

  66. 2022

    Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives

  67. 2022

    Pharmacological treatment of tremor in multiple sclerosis; a systematic review

    InconclusivoMetanálise ClínicaEsclerose Múltipla
  68. 2022

    Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice

  69. 2022

    Potential anti-Parkinsonian's effect of S-(+)-linalool from Cinnamomum osmophloeum ct. linalool leaves are associated with mitochondrial regulation via gas-1, nuo-1, and mev-1 in Caenorhabditis elegans

    FavorávelEstudo LaboratorialDoença de Parkinson
  70. 2022

    Role of Cannabinoids in Various Diseases: A Review

  71. 2022

    Single and Repeated Exposure to Cannabidiol Differently Modulate BDNF Expression and Signaling in the Cortico-Striatal Brain Network

    FavorávelEstudo em AnimaisTranstornos de ComportamentoCanabigerol (CBG)
  72. 2022

    The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes

    FavorávelMetanálise ClínicaDorCâncerAnsiedade+5
  73. 2022

    The Effect of Cannabidiol Coated by Nano-Chitosan on Learning and Memory, Hippocampal CB1 and CB2 Levels, and Amyloid Plaques in an Alzheimer's Disease Rat Model

    FavorávelEstudo em AnimaisDoença de AlzheimerDemência
  74. 2022

    The endocannabinoid system as a target for the treatment of neuronal damage

    FavorávelMetanáliseInflamaçãoEstresse OxidativoExcitotoxicidade
  75. 2022

    The Food Additive β-Caryophyllene Exerts Its Neuroprotective Effects Through the JAK2-STAT3-BACE1 Pathway

    FavorávelEstudo LaboratorialDoença de Alzheimer
  76. 2022

    The Memory Benefit to Aged APP/PS1 Mice from Long-Term Intranasal Treatment of Low-Dose THC

  77. 2022

    The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?

  78. 2022

    The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials

    FavorávelMetanálise ClínicaDorCâncerEfeitos Adversos da CannabisTHC Farmacêutico+7
  79. 2022

    Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence

    FavorávelMetanálise ClínicaDorInflamaçãoDisfunção CognitivaPalmitoiletanolamida (PEA)+8
  80. 2022

    Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals

  81. 2022

    What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?

  82. 2021

    A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT 1A Receptors

    FavorávelEstudo LaboratorialEstresse OxidativoCanabigerol (CBG)
  83. 2021

    A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid

  84. 2021

    A Review of the Current Evidence Connecting Seborrheic Dermatitis and Parkinson's Disease and the Potential Role of Oral Cannabinoids

    FavorávelMetanáliseInflamaçãoDoença de ParkinsonSeborreia
  85. 2021

    A systematic, integrative review of the effects of the endocannabinoid system on inflammation and neurogenesis in animal models of affective disorders

  86. 2021

    Adverse Effects of Recreational and Medical Cannabis

    InconclusivoMetanáliseDorEfeitos Adversos da CannabisDependência — Cannabis+1
  87. 2021

    Adverse Effects of Recreational and Medical Cannabis

    InconclusivoMetanáliseDorEfeitos Adversos da CannabisDor — Crônica+2
  88. 2021

    An Agathokakological Tale of Δ 9-THC: Exploration of Possible Biological Targets

    FavorávelMetanáliseDoenças Cardiovasculares (DCV)
  89. 2021

    Cannabidiol - A phytocannabinoid that widely affects sphingolipid metabolism under conditions of brain insulin resistance

    FavorávelEstudo em AnimaisObesidadeDoença de AlzheimerDiabetes+1
  90. 2021

    Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic

    DesfavorávelMetanáliseInflamaçãoInfecções BacterianasCOVID-19CBD Farmacêutico
  91. 2021

    Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action

    FavorávelMetanáliseCâncerEpilepsiaEsclerose Múltipla+1
  92. 2021

    Cannabidiol in the management of bruxism in behavioral variant of frontotemporal degeneration

    FavorávelMetanáliseDisfunção CognitivaTranstornos de Comportamento
  93. 2021

    Cannabidiol prevents lipopolysaccharide-induced sickness behavior and alters cytokine and neurotrophic factor levels in the brain

    FavorávelEstudo em AnimaisInflamaçãoDepressão
  94. 2021

    Cannabidiol Signaling in the Eye and Its Potential as an Ocular Therapeutic Agent

    FavorávelMetanáliseDorInflamaçãoEstresse Oxidativo+4
  95. 2021

    Cannabidiol: pharmacology and therapeutic targets

    FavorávelMetanáliseDorInflamaçãoDor — Crônica+4
  96. 2021

    Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

    InconclusivoEstudo em AnimaisDoença de Alzheimer
  97. 2021

    Cannabinoids for major neurocognitive disorder: case report and literature review

    FavorávelMetanálise
  98. 2021

    Cannabinoids in Neurologic Illnesses

    InconclusivoMetanálise
  99. 2021

    Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson's Disease

    DesfavorávelMetanáliseDorEfeitos Adversos da CannabisDor — CrônicaTHC Farmacêutico+4
  100. 2021

    Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101

    DesfavorávelEstudo em AnimaisDorInflamaçãoEfeitos Adversos da Cannabis+5
  101. 2021

    Effect of α-pinene and thymoquinone on the differentiation of bone marrow mesenchymal stem cells into neuroprogenitor cells

    FavorávelEstudo Laboratorial
  102. 2021

    Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeDepressãoTDA e TDAHAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
  103. 2021

    Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research

    FavorávelMetanáliseDorDependência QuímicaCâncer+16
  104. 2021

    In Vitro Studies on Therapeutic Effects of Cannabidiol in Neural Cells: Neurons, Glia, and Neural Stem Cells

    FavorávelMetanáliseInflamação
  105. 2021

    Linalool Alleviates A β 42-Induced Neurodegeneration via Suppressing ROS Production and Inflammation in Fly and Rat Models of Alzheimer's Disease

    FavorávelEstudo em AnimaisInflamaçãoDoença de Alzheimer
  106. 2021

    Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review

  107. 2021

    Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects

    FavorávelMetanáliseDorCâncerAnsiedade+5
  108. 2021

    Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19?

    FavorávelMetanáliseDorCâncerDor — Crônica+5
  109. 2021

    Mediterranean Diet and Neurodegenerative Diseases: The Neglected Role of Nutrition in the Modulation of the Endocannabinoid System

    FavorávelMetanáliseInflamaçãoDieta
  110. 2021

    Myrcene—What Are the Potential Health Benefits of This Flavouring and Aroma Agent?

    FavorávelMetanáliseDorCâncerInflamaçãoEndocanabinoide (não especificado)+9
  111. 2021

    Neurobiological Processes Induced by Aerobic Exercise through the Endocannabinoidome

  112. 2021

    Neuroprotective effect of α-pinene self-emulsifying nanoformulation against 6-OHDA induced neurotoxicity on human SH-SY5Y cells and its in vivo validation for anti-Parkinson's effect

    FavorávelEstudo em AnimaisEstresse OxidativoDoença de Parkinson
  113. 2021

    Neuroprotective Effects of Cannabidiol but Not Δ9-Tetrahydrocannabinol in Rat Hippocampal Slices Exposed to Oxygen-Glucose Deprivation: Studies with Cannabis Extracts and Selected Cannabinoids

    InconclusivoEstudo LaboratorialInflamaçãoAVCCanabinol (CBN)Ácido Canabidiólico (CBD-a)+2
  114. 2021

    Neuroprotective Potential of Limonene and Limonene Containing Natural Products

    FavorávelMetanáliseAnsiedadeEpilepsiaEsclerose Múltipla+2
  115. 2021

    Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases

  116. 2021

    Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition

  117. 2021

    Potential role of cannabidiol in Parkinson’s disease by targeting the WNT/β-catenin pathway, oxidative stress and inflammation

    FavorávelMetanáliseInflamaçãoEstresse OxidativoDoença de Parkinson
  118. 2021

    PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice

    FavorávelEstudo em AnimaisInflamaçãoDisfunção CognitivaPsicose
  119. 2021

    Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases

  120. 2021

    Quality of Life and a Surveillant Endocannabinoid System

  121. 2021

    Recent updates on bioactive properties of linalool

    FavorávelMetanáliseCâncerAnsiedadeDepressão+1
  122. 2021

    Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials

    FavorávelMetanálise ClínicaDorDor — CrônicaEsclerose MúltiplaTHC:CBD Farmacêutico+5
  123. 2021

    Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports

    FavorávelMetanáliseDorDor — CrônicaEsclerose MúltiplaTHC:CBD Farmacêutico+1
  124. 2021

    Systematic review of the impact of cannabinoids on neurobehavioral outcomes in preclinical models of traumatic and nontraumatic spinal cord injury

  125. 2021

    The cannabinoid system and microglia in health and disease

  126. 2021

    The Current and Potential Application of Medicinal Cannabis Products in Dentistry

  127. 2021

    The Endocannabinoid System: A Bridge between Alzheimer's Disease and Gut Microbiota

  128. 2021

    The Neuroprotective properties, Functions and Roles of Cannabis sativa in selected diseases related to the Nervous System

  129. 2021

    The Role of Cannabidiol in Neurological Disorders

    FavorávelMetanáliseDisfunção CognitivaEsclerose MúltiplaDoença de Alzheimer+8
  130. 2021

    Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease

    FavorávelMetanáliseDisfunção CognitivaDoença de AlzheimerCBD Farmacêutico
  131. 2020

    A Literature Analysis on Medicinal Use and Research of Cannabis in the Meiji Era of Japan

    FavorávelMetanáliseDorDor — CrônicaInsônia e Distúrbios do Sono+3
  132. 2020

    A systematic review of minor phytocannabinoids with promising neuroprotective potential

  133. 2020

    Astrocytic palmitoylethanolamide pre-exposure exerts neuroprotective effects in astrocyte-neuron co-cultures from a triple transgenic mouse model of Alzheimer's disease

  134. 2020

    Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?

  135. 2020

    Cannabidiol (CBD)

    FavorávelMetanáliseInflamaçãoAnsiedadeEpilepsia+4
  136. 2020

    Cannabis sativa: Much more beyond Δ 9-tetrahydrocannabinol

    FavorávelMetanáliseDorDor — CrônicaEpilepsia+1
  137. 2020

    Chronic Treatment with 50 mg/kg Cannabidiol Improves Cognition and Moderately Reduces Aβ40 Levels in 12-Month-Old Male AβPPswe/PS1ΔE9 Transgenic Mice

    FavorávelEstudo em AnimaisInflamaçãoDisfunção CognitivaTranstornos de Comportamento+1
  138. 2020

    Current application of cannabidiol (CBD) in the management and treatment of neurological disorders

    FavorávelMetanálise
  139. 2020

    Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease

    FavorávelMetanáliseDorInflamaçãoDisfunção Cognitiva+2
  140. 2020

    Endocannabinoid modulation of dopamine release during reward seeking, interval timing, and avoidance

  141. 2020

    Endocannabinoid Signaling for GABAergic-Microglia (Mis)Communication in the Brain Aging

    FavorávelMetanáliseDisfunção CognitivaCondições GeriátricasLongevidade
  142. 2020

    Food supplements based on palmitoylethanolamide plus hydroxytyrosol from olive tree or Bacopa monnieri extracts for neurological diseases

  143. 2020

    From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases

    FavorávelMetanáliseInflamaçãoEstresse OxidativoDoença de Alzheimer+1
  144. 2020

    GPR6 Structural Insights: Homology Model Construction and Docking Studies

  145. 2020

    Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity

  146. 2020

    Industrial Hemp (Cannabis sativa subsp. sativa) as an Emerging Source for Value-Added Functional Food Ingredients and Nutraceuticals

    FavorávelMetanáliseCâncerAnsiedadeDoenças Cardiovasculares (DCV)+6
  147. 2020

    Is 1,8-Cineole-Rich Extract of Small Cardamom Seeds More Effective in Preventing Alzheimer's Disease than 1,8-Cineole Alone?

    FavorávelEstudo LaboratorialDoença de AlzheimerMedicina Mente-Corpo
  148. 2020

    Isomeric O-methyl cannabidiolquinones with dual BACH1/NRF2 activity

    FavorávelEstudo LaboratorialInflamaçãoEstresse OxidativoDoença de Alzheimer+3
  149. 2020

    Lysophosphatidylinositol, an Endogenous Ligand for G Protein-Coupled Receptor 55, Has Anti-inflammatory Effects in Cultured Microglia

  150. 2020

    Melatonin and cannabinoids: mitochondrial-targeted molecules that may reduce inflammaging in neurodegenerative diseases

    FavorávelMetanáliseInflamaçãoEstresse OxidativoDoença de Alzheimer+2
  151. 2020

    Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease

  152. 2020

    Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone

  153. 2020

    Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries—A Systematic Review

  154. 2020

    Terpenes/Terpenoids in Cannabis: Are They Important?

    FavorávelMetanáliseDorCâncerInflamação+10
  155. 2020

    The Cannabis Terpenes

    FavorávelMetanáliseDorCâncerInflamação+10
  156. 2020

    The Endocannabinoid System May Modulate Sleep Disorders in Aging

  157. 2020

    Understanding Cannabis-Based Therapeutics in Sports Medicine

    FavorávelMetanáliseDorDor — CrônicaEstresse Oxidativo+4
  158. 2020

    β-Caryophyllene nanoparticles design and development: Controlled drug delivery of cannabinoid CB2 agonist as a strategic tool towards neurodegeneration

    FavorávelEstudo Laboratorial
  159. 2019

    24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone

  160. 2019

    A Review on Studies of Marijuana for Alzheimer's Disease - Focusing on CBD, THC

  161. 2019

    Adverse Effects of Cannabis Use on Neurocognitive Functioning: A Systematic Review of Meta- Analytic Studies

    DesfavorávelMetanáliseEfeitos Adversos da CannabisTranstornos de Comportamento
  162. 2019

    Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation

    FavorávelEnsaio Clínico Duplo-CegoInflamaçãoEstresse OxidativoDoença de AlzheimerTHC Farmacêutico
  163. 2019

    Association of CNR1 genotypes with changes in neurocognitive performance after eighteen-month treatment in patients with first-episode psychosis

    InconclusivoMetanáliseDisfunção CognitivaPsicoseEsquizofrenia
  164. 2019

    Cannabidiol Protects Dopaminergic Neuronal Cells from Cadmium

    FavorávelEstudo Laboratorial
  165. 2019

    Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice

    FavorávelEstudo em AnimaisDisfunção CognitivaSíndrome de RettCanabidivarina (CBDV)
  166. 2019

    Effects of Cannabis sativa extract on haloperidol-induced catalepsy and oxidative stress in the mice

    FavorávelEstudo em AnimaisEstresse OxidativoEsclerose MúltiplaDoença de Parkinson+2
  167. 2019

    Elevated Levels of Arachidonic Acid-Derived Lipids Including Prostaglandins and Endocannabinoids Are Present Throughout ABHD12 Knockout Brains: Novel Insights Into the Neurodegenerative Phenotype

    InconclusivoEstudo em AnimaisCondições GeriátricasCatarata2-Araquidonoilglicerol (2-AG)
  168. 2019

    Endocannabinoid system in the neurodevelopment of GABAergic interneurons: implications for neurological and psychiatric disorders

  169. 2019

    Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders

    DesfavorávelMetanáliseEsquizofrenia
  170. 2019

    Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders

    FavorávelMetanáliseAnsiedadeDepressãoEpilepsia+3
  171. 2019

    Heavy cannabis use, dependence and the brain: a clinical perspective

    InconclusivoMetanáliseDependência — CannabisTetraidrocanabinol (THC)
  172. 2019

    Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva

    FavorávelEnsaio ClínicoDisfunção CognitivaDoença de AlzheimerDemência
  173. 2019

    Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review

    FavorávelMetanáliseTHC Farmacêutico
  174. 2019

    Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

    FavorávelEnsaio Clínico Duplo-CegoEsclerose Lateral Amiotrófica (ELA)THC:CBD Farmacêutico
  175. 2019

    Selective Modulator of Cannabinoid Receptor Type 2 Reduces Memory Impairment and Infarct Size During Cerebral Hypoperfusion and Vascular Dementia

    FavorávelEstudo em AnimaisDisfunção CognitivaDoença de AlzheimerDemência
  176. 2018

    Anti-Inflammatory, Antioxidative, and Hepatoprotective Effects of Trans Δ9-Tetrahydrocannabinol/Sesame Oil on Adjuvant-Induced Arthritis in Rats.

  177. 2018

    Biphasic effects of THC in memory and cognition.

  178. 2018

    Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia

    FavorávelMetanáliseDoença de AlzheimerPerda de Apetite
  179. 2018

    Cannabis Therapeutics and the Future of Neurology

  180. 2018

    In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid

    FavorávelEstudo LaboratorialInflamaçãoEstresse OxidativoEsclerose MúltiplaCanabigerol (CBG)+2
  181. 2018

    Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B

    InconclusivoEstudo LaboratorialVirodamina (O-AEA)
  182. 2018

    Linalool bioactive properties and potential applicability in drug delivery systems

    FavorávelMetanáliseDorCâncerInflamaçãoMedicina Mente-Corpo+9
  183. 2018

    N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice

    FavorávelEstudo em AnimaisDoença de ParkinsonPalmitoiletanolamida (PEA)
  184. 2018

    Palmitoylethanolamide Blunts Amyloid-β42-Induced Astrocyte Activation and Improves Neuronal Survival in Primary Mouse Cortical Astrocyte-Neuron Co-Cultures

    FavorávelEstudo LaboratorialInflamaçãoDoença de AlzheimerPalmitoiletanolamida (PEA)
  185. 2018

    Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: In Vitro and In Vivo Evidence

    FavorávelEstudo em AnimaisDoença de AlzheimerPalmitoiletanolamida (PEA)
  186. 2018

    Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti-inflammatory and neuroprotective effects

    FavorávelEstudo em AnimaisDoença de AlzheimerPalmitoiletanolamida (PEA)
  187. 2018

    β-Caryophyllene (BCP) ameliorates MPP+ induced cytotoxicity.

    FavorávelEstudo LaboratorialEstresse OxidativoDoença de ParkinsonCapsaicina (CAPS)
  188. 2018

    Δ9-Tetrahydrocannabinol Prevents Cardiovascular Dysfunction in STZ-Diabetic Wistar-Kyoto Rats.

    FavorávelEstudo em AnimaisDoenças Cardiovasculares (DCV)Estresse OxidativoDiabetes
  189. 2017

    A Chronic Low Dose Of Δ9-tetrahydrocannabinol (THC) Restores Cognitive Function In Old Mice

  190. 2017

    A Pulsed Electromagnetic Field Protects against Glutamate-Induced Excitotoxicity by Modulating the Endocannabinoid System in HT22 Cells

    FavorávelEstudo LaboratorialExcitotoxicidadeAnandamida (AEA)Endocanabinoide (não especificado)+4
  191. 2017

    A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia

    FavorávelMetanáliseInflamaçãoDisfunção CognitivaPsicose+5
  192. 2017

    Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neuron.

    FavorávelEstudo LaboratorialDoenças Cardiovasculares (DCV)AVCLesão de Reperfusão
  193. 2017

    Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke.

    FavorávelEstudo em AnimaisAVC
  194. 2017

    Cannabinoid Receptor 2 Signaling In Neurodegenerative Disorders: From Pathogenesis To A Promising Therapeutic Target

  195. 2017

    Deletion of Type-2 Cannabinoid Receptor Induces Alzheimer's Disease-Like Tau Pathology and Memory Impairment Through AMPK/GSK3β Pathway

    FavorávelEstudo em AnimaisDoença de AlzheimerEndocanabinoide (não especificado)
  196. 2017

    Extract of Fructus Cannabis Ameliorates Learning and Memory Impairment Induced by D-Galactose in an Aging Rats Model.

    FavorávelEstudo em AnimaisDisfunção CognitivaEstresse Oxidativo
  197. 2017

    High-Dose Cannabidiol Induced Hypotension after Global Hypoxia-Ischemia in Piglets

    InconclusivoEstudo em AnimaisDoenças Cardiovasculares (DCV)Alterações Cerebrais Neonatais
  198. 2017

    Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

  199. 2017

    Neuroprotective Effect of β-Caryophyllene on Cerebral Ischemia-Reperfusion Injury via Regulation of Necroptotic Neuronal Death and Inflammation: In Vivo and in Vitro

    FavorávelEstudo em AnimaisDoenças Cardiovasculares (DCV)AVCLesão de Reperfusão
  200. 2017

    Plastic And Neuroprotective Mechanisms Involved In The Therapeutic Effects Of Cannabidiol In Psychiatric Disorders

    FavorávelMetanáliseAnsiedadeDepressãoPsicose+1
  201. 2017

    Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy.

    FavorávelEstudo em AnimaisEpilepsia
  202. 2017

    Risk of neonatal and childhood morbidity among preterm infants exposed to marijuana

    InconclusivoEnsaio ClínicoEfeitos Adversos da CannabisGestaçãoAlterações Cerebrais Neonatais+2
  203. 2017

    Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients

    FavorávelEnsaio ClínicoDorInflamaçãoDor — CrônicaTHC:CBD Farmacêutico+1
  204. 2017

    Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology

    FavorávelEnsaio ClínicoInflamaçãoAnsiedadeDepressãoTHC:CBD Farmacêutico+3
  205. 2017

    Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease

  206. 2017

    Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.

    FavorávelEstudo em AnimaisDoença de HuntingtonTetraidrocanabinol (THC)Canabigerol (CBG)+3
  207. 2017

    The cannabinoid beta-caryophyllene (BCP) induces neuritogenesis in PC12 cells by a cannabinoid-receptor-independent mechanism.

    FavorávelEstudo LaboratorialEstresse Oxidativo
  208. 2017

    The Experiences of Medical Marijuana Patients: A Scoping Review of the Qualitative Literature.

  209. 2017

    The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations

    FavorávelMetanáliseDorInflamaçãoDor — CrônicaPalmitoiletanolamida (PEA)+7
  210. 2017

    Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson's Disease

    FavorávelEnsaio ClínicoInflamaçãoDoença de ParkinsonPalmitoiletanolamida (PEA)
  211. 2017

    β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis

  212. 2016

    A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease

  213. 2016

    Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy

    FavorávelEnsaio ClínicoEsclerose Lateral Amiotrófica (ELA)Palmitoiletanolamida (PEA)
  214. 2016

    Cannabidiol, neuroprotection and neuropsychiatric disorders.

    FavorávelMetanáliseInflamaçãoAnsiedadeDoenças Cardiovasculares (DCV)+8
  215. 2016

    Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease

    FavorávelEstudo em AnimaisEstresse OxidativoDoença de ParkinsonCanabinoides Sintéticos AM-x
  216. 2016

    Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.

  217. 2016

    Cannabis - the Israeli perspective

  218. 2016

    Dietary Omega-6/Omega-3 and Endocannabinoids: Implications for Brain Health and Diseases

    FavorávelMetanáliseAnsiedadeDepressãoÔmega-3Ômega-6
  219. 2016

    Distinctive effects of eicosapentaenoic and docosahexaenoic acids in regulating neural stem cell fate are mediated via endocannabinoid signalling pathways

    InconclusivoEstudo em AnimaisAVC2-Araquidonoilglicerol (2-AG)Ômega-3
  220. 2016

    Effects of Cannabidiol and Hypothermia on Short-Term Brain Damage in New-Born Piglets after Acute Hypoxia-Ischemia.

    FavorávelEstudo em AnimaisEstresse OxidativoAlterações Cerebrais Neonatais
  221. 2016

    Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis

    FavorávelEnsaio ClínicoDorInflamaçãoDor — CrônicaTHC:CBD Farmacêutico+4
  222. 2016

    Functional validation of ABHD12 mutations in the neurodegenerative disease PHARC.

    DesfavorávelEstudo em AnimaisDorDor — Polineuropatia InflamatóriaDoenças da Retina+2
  223. 2016

    Modulation of cellular redox homeostasis by the endocannabinoid system.

  224. 2016

    Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone

    FavorávelEstudo em AnimaisInflamaçãoEstresse OxidativoDoença de Parkinson
  225. 2016

    Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDor — CrônicaAnandamida (AEA)Palmitoiletanolamida (PEA)+2
  226. 2016

    Short-term effects of cannabidiol after global hypoxia-ischemia in newborn piglets.

    InconclusivoEstudo em AnimaisEstresse OxidativoAlterações Cerebrais Neonatais
  227. 2016

    Type-2 cannabinoid receptors in neurodegeneration

  228. 2016

    Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®

    FavorávelEnsaio ClínicoEsclerose MúltiplaTHC:CBD Farmacêutico
  229. 2016

    β‐caryophyllene and β‐caryophyllene oxide—natural compounds of anticancer and analgesic properties.

    FavorávelMetanáliseDorCâncerInflamação+16
  230. 2015

    Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria.

    FavorávelEstudo em AnimaisAnsiedadeDisfunção CognitivaMalária
  231. 2015

    Cannabinoids In Neurodegenerative Disorders And Stroke/Brain Trauma: From Preclinical Models To Clinical Applications

    FavorávelMetanáliseDoença de AlzheimerDoença de ParkinsonAVC+3
  232. 2015

    Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review

    FavorávelMetanáliseDorDependência QuímicaDependência — Cannabis+16
  233. 2015

    Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others

  234. 2015

    Neurocognitive and social cognitive predictors of cannabis use in first-episode psychosis

  235. 2015

    Palmitoylethanolamide Inhibits Glutamate Release in Rat Cerebrocortical Nerve Terminals

  236. 2015

    Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection

  237. 2015

    The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis

  238. 2015

    The neuroprotection of cannabidiol against MPP(+)-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease.

  239. 2015

    Ultra Low Dose Delta 9-Tetrahydrocannabinol Protects Mouse Liver from Ischemia Reperfusion Injury.

  240. 2014

    A New Generation Fatty Acid Amide Hydrolase Inhibitor Protects Against Kainate-induced Excitotoxicity.

  241. 2014

    A restricted population of CB1 cannabinoid receptors with neuroprotective activity.

    FavorávelEstudo em AnimaisDoença de Huntington
  242. 2014

    Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

  243. 2014

    Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro

    FavorávelEstudo Laboratorial2-Araquidonoilglicerol (2-AG)Canabinoides Sintéticos JWH-x+2
  244. 2014

    Harnessing the anti-inflammatory potential of palmitoylethanolamide

  245. 2014

    Palmitoylethanolamide in CNS health and disease

  246. 2014

    Protective effects of geraniol (a monoterpene) in a diabetic neuropathy rat model: attenuation of behavioral impairments and biochemical perturbations

    FavorávelEstudo em AnimaisInflamaçãoEstresse OxidativoDiabetes+2
  247. 2014

    Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage.

  248. 2013

    Antioxidant effects of nerolidol in mice hippocampus after open field test.

    FavorávelEstudo em AnimaisAnsiedadeEstresse Oxidativo
  249. 2013

    Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

  250. 2013

    Cannabinoids: Well-Suited Candidates for the Treatment of Perinatal Brain Injury.

  251. 2013

    Effect of diet on tissue levels of palmitoylethanolamide

  252. 2013

    Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

    InconclusivoEnsaio Clínico Duplo-CegoDorInflamaçãoDor — CrônicaTHC Farmacêutico+2
  253. 2013

    Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs

    FavorávelEstudo em AnimaisDorCâncerPsicoseTHC Farmacêutico+10
  254. 2013

    Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator

    FavorávelMetanáliseInflamaçãoAnandamida (AEA)Palmitoiletanolamida (PEA)+1
  255. 2013

    The endocannabinoid system and the brain

  256. 2013

    Two novel mutations in ABHD12: expansion of the mutation spectrum in PHARC and assessment of their functional effects.

  257. 2012

    A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury

  258. 2012

    Cannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury.

    FavorávelEstudo em AnimaisLesões da Medula Espinhal
  259. 2012

    Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures.

    FavorávelEstudo LaboratorialEstresse OxidativoÁcido Tetraidrocanabinólico (THC-a)
  260. 2012

    Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases

  261. 2012

    Mast cell–glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide

  262. 2012

    Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders.

    FavorávelEstudo em AnimaisDisfunção Cognitiva
  263. 2012

    Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB1 and CB2 Receptors.

  264. 2012

    Single-dose Pharmacokinetics and Tolerability of Oral Delta-9- Tetrahydrocannabinol in Patients with Amyotrophic Lateral Sclerosis

    DesfavorávelEnsaio Clínico
  265. 2012

    Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease

    InconclusivoMetanálise ClínicaDorEsclerose Lateral Amiotrófica (ELA)Tetraidrocanabinol (THC)
  266. 2011

    Prospects for cannabinoid therapies in basal ganglia disorders.

    FavorávelMetanáliseInflamaçãoDoença de ParkinsonDoença de Huntington
  267. 2011

    The multiplicity of action of cannabinoids: implications for treating neurodegeneration

  268. 2011

    Therapeutic potential of the endocannabinoid system in perinatal asphyxia.

  269. 2010

    Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington’s disease.

    FavorávelEstudo em AnimaisDoença de HuntingtonCanabinoides Sintéticos SR-x
  270. 2010

    Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality

  271. 2010

    Mutations in ABHD12 Cause the Neurodegenerative Disease PHARC: An Inborn Error of Endocannabinoid Metabolism

  272. 2010

    THC Prevents MDMA Neurotoxicity in Mice.

    FavorávelEstudo em AnimaisTetraidrocanabinol (THC)Canabinoides Sintéticos AM-x
  273. 2009

    Cannabidiol: a promising drug for neurodegenerative disorders?

    FavorávelMetanáliseDoença de Parkinson
  274. 2009

    Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis

  275. 2009

    Cannabinoids for the treatment of dementia

    InconclusivoMetanálise ClínicaDemência
  276. 2009

    Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

    FavorávelMetanáliseCâncerInflamaçãoObesidadeTetraidrocanabivarina (THCV)+1
  277. 2009

    Selective CB2 Receptor Agonism Protects Central Neurons from Remote Axotomy-Induced Apoptosis through the PI3K/Akt Pathway.

  278. 2008

    A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner

  279. 2008

    Targeting the endocannabinoid system: to enhance or reduce?

  280. 2007

    Cannabinoids and neuroprotection in basal ganglia disorders.

    FavorávelMetanáliseInflamaçãoDoenças Cardiovasculares (DCV)Estresse Oxidativo+4
  281. 2007

    Cannabinoids in health and disease

  282. 2007

    Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor‐independent myeloperoxidase‐inhibiting mechanism.

    FavorávelEstudo em AnimaisAVCTetraidrocanabinol (THC)Canabinoides Sintéticos AM-x+1
  283. 2007

    Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies

    FavorávelMetanáliseDoença de AlzheimerDoença de ParkinsonÔmega-3
  284. 2006

    Increasing Cannabinoid Levels By Pharmacological And Genetic Manipulation Delay Disease Progression In SOD1 Mice

  285. 2006

    Multiple sclerosis may disrupt endocannabinoid brain protection mechanism

  286. 2006

    Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes.

    FavorávelEstudo em AnimaisEstresse OxidativoDiabetesDoenças da Retina
  287. 2005

    Cannabinoids Promote Embryonic And Adult Hippocampus Neurogenesis And Produce Anxiolytic- And Antidepressant-like Effects

    FavorávelEstudo em AnimaisAnsiedadeDepressãoDisfunção CognitivaCanabinoides Sintéticos HU-x+1
  288. 2005

    Cannabinoids: between neuroprotection and neurotoxicity

  289. 2005

    Cannabinol Delays Symptom Onset In SOD1 (G93A) Transgenic Mice Without Affecting Survival

    FavorávelEstudo em AnimaisEsclerose Lateral Amiotrófica (ELA)Canabinol (CBN)
  290. 2005

    Comparison of Cannabidiol, Antioxidants, and Diuretics in Reversing Binge Ethanol-Induced Neurotoxicity.

    FavorávelEstudo em AnimaisDependência QuímicaDisfunção CognitivaEstresse Oxidativo+2
  291. 2005

    Inhibition of Acetylcholinesterase Activity by Bicyclic Monoterpenoids

    FavorávelEstudo LaboratorialDisfunção Cognitiva
  292. 2003

    Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

    InconclusivoEnsaio Clínico Duplo-CegoEsclerose Múltipla
  293. 2002

    Cannabidiol: an overview of some pharmacological aspects

    FavorávelMetanáliseAnsiedadeEpilepsiaPsicoseAnandamida (AEA)+4
  294. 2001

    Neuroprotection by Δ9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity

  295. 1999

    Cannabinoids as antioxidants and neuroprotectants.

  296. 1998

    Cannabidiol and Delta9-tetrahydrocannabinol are neuroprotective antioxidants.

    FavorávelEstudo LaboratorialEstresse OxidativoTetraidrocanabinol (THC)
  297. 1998

    Cannabidiol and Delta9-tetrahydrocannabinol are neuroprotective antioxidants.

    FavorávelEstudo LaboratorialAVCTetraidrocanabinol (THC)Canabinoides Sintéticos SR-x+1
  298. 1993

    The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6- tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain

    FavorávelEstudo LaboratorialExcitotoxicidadeCanabinoides Sintéticos HU-x
  299. 1981

    Tetrahydrocannabinol potentiates reserpine-induced hypokinesia

    FavorávelEstudo em AnimaisDoença de ParkinsonDoença de HuntingtonCoreia

Continue por aqui

Perguntas frequentes

Quantos estudos sobre doenças neurodegenerativas estão indexados no acervo?
São 299 estudos, publicados entre 1981 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 143 · Estudo em Animais: 81 · Estudo Laboratorial: 38 · Ensaio Clínico Duplo-Cego: 15 · Ensaio Clínico: 11 · Metanálise Clínica: 11. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 250 favoráveis, 35 inconclusivos e 14 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Doenças Neurodegenerativas — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/doencas-neurodegenerativas/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Doenças Neurodegenerativas — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/doencas-neurodegenerativas/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.